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Human liver stem cells (HLSCs) are a mesenchymal stromal cell-like population resident in the adult liver. Preclinical studies
indicate that HLSCs could be a good candidate for cell therapy. The aim of the present study was to evaluate the immunogenicity
and the immunomodulatory properties of HLSCs on T-lymphocytes, natural killer cells (NKs), and dendritic cells (DCs) in
allogeneic experimental settings. We found that HLSCs inhibited T-cell proliferation by a mechanism independent of cell contact
and dependent on the release of prostaglandin E2 (PGE
2
) and on indoleamine 2,3-dioxygenase activity. When compared with
mesenchymal stromal cells (MSCs), HLSCs were more efficient in inhibiting T-cell proliferation. At variance with MSCs, HLSCs
did not elicit NK degranulation.Moreover, HLSCs inhibitedNKdegranulation against K562, a NK-sensitive target, by amechanism
dependent on HLA-G release. When tested on DC generation from monocytes, HLSCs were found to impair DC differentiation
and DCs ability to induce T-cell proliferation through PGE
2
. This study shows that HLSCs have immunomodulatory properties
similar to MSCs, but, at variance with MSCs, they do not elicit a NK response.
1. Introduction
Human liver stem cells (HLSCs) have been identified and
characterized as a mesenchymal stromal cell-like popula-
tion derived from adult human liver [1]. This population
possesses many surface markers in common with bone
marrow-derived mesenchymal stromal cells (MSCs) such as
CD29, CD73, CD44, CD105, and CD146; in addition, they
express specific hepatic cell markers (albumin, cytokeratin-
8, and cytokeratin-18) and embryonic markers (Nanog,
Oct3/4, Sox2, Musashi, SSEA4, and Pax2) [1, 2]. HLSCs
are able to differentiate into osteocytes, endothelial cells,
hepatocytes, and beta-like cells [1–3]. When injected in
different experimental models of liver failure, HLSCs engraft
in injured liver and improve liver function and morphology
[1, 2]. In particular, HLSCs have been described to protect
SCID mice with fulminant liver failure from death by direct
differentiation into hepatocytes and by secreting soluble
factors that limit the injury [2]. Moreover, HLSCs are able
to improve recovery also of different organs, such as kidneys
[4]. Being potential candidates for clinical application, it
is important to investigate the immunogenicity of HLSCs
and their interaction with the immune system. In fact, a
common complication in allogeneic cell therapies is the
immune rejection. However, therapy with allogeneic MSCs
of different origin is facilitated by their low immunogenicity
and immunomodulatory properties [5, 6].
The aim of the present study was to evaluate whether
HLSCs could modulate the behavior of immune cells, in
comparison with MSCs. In particular, we investigated the
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effects of HLSCs on T-lymphocytes, natural killer cells (NKs),
and dendritic cells (DCs) in allogeneic experimental settings.
2. Materials and Methods
2.1. Culture of HLSCs and MSCs. HLSCs were isolated from
human cryopreserved normal adult hepatocytes purchased
fromLonza (Basel, Switzerland) andwere cultured as described
[1–4]. Briefly, hepatocytes were initially cultured for 2 weeks
in hepatozyme-SFM medium at a density of 1.0–1.5 × 105
viable cells per cm2. After 2 weeks, most of the hepatocytes
died, and then medium was substituted by 𝛼-MEM/EBM-1
(3 : 1) (Lonza) media supplemented with l-glutamine (5mM),
HEPES (12mM, pH 7.4), penicillin (50 IU/mL), streptomycin
(50𝜇g/mL) (all from Sigma, St. Louis, MO, USA), and
fetal calf serum (FCS) (10%) (Invitrogen). When HLSC
colonies were evident, cells were expanded and characterized.
HLSCs expressed some MSC markers (CD29, CD44, CD73,
CD90, and CD105), specific hepatic markers (albumin, 𝛼-
fetoprotein, cytokeratin-8, and cytokeratin-18), and some
embryonic stem cell markers (Oct3/4, Nanog, Pax2,Musashi,
SSEA4, and Sox2) as previously described [1–3]. By cytoflu-
orimetric analysis (FACS), conducted with FACSCalibur
cytometer (Becton Dickinson Bioscience, San Jose´, CA), the
expression of costimulatory molecules and histocompatibil-
ity antigens, CD40, CD80, CD86, HLA class I, and HLA-DR
(all from Becton Dickinson), was evaluated (dilution 1 : 20).
HLSCs obtained from each preparation showed the same
phenotype and they were used within the 10th passages.
The expression of human leukocyte antigen G (HLA-G,
dilution 1 : 20) on HLSCs was evaluated by FACS analyses
using the specificMEMG/9 antibody (native form for human
HLA-G1, EXBIO, Praha, CzechRepublic). Extracellular stain-
ing and intracellular staining were used to study membrane-
bound and intracytoplasmic HLA-G protein.
Bone marrow MSCs were purchased from Lonza, cul-
tured, and characterized as previously described [2].
2.2. Peripheral Blood Mononuclear Cells Isolation. Periph-
eral blood mononuclear cells (PBMCs) were obtained from
healthy donors (𝑛 = 3 males; 𝑛 = 7 female and age 25–40
years old). All subjects gave informed consent and the study
was approved by the local Ethical ReviewBoard. PBMCswere
isolated by centrifugation over Histopaque-1077 (Sigma).
2.3. T-Cell Purification and Culture. CD3-positive cells were
sorted from PBMCs using immunomagnetic beads (Milte-
nyi Biotec, Cologne, Germany) and used in coculture exper-
iments. PBMCs were characterized to typify HLA Class I
and HLA Class II expression (Supplementary Table 1 in Sup-
plementary Material available online at http://dx.doi.org/
10.1155/2016/8468549). To this purpose DNA was extracted
and Luminex technology was used (One Lambda, Thermo
Fisher). Luminex technology uses sequence-specific oligonu-
cleotide probes bound to color-coded microbeads in order to
identify HLA alleles encoded by the DNA sample. As shown
in Supplementary Table 1, different donors had differentHLA
class I andHLAclass II phenotype andweremismatchedwith
HLSCs.
The purity of CD3+ was 98 ± 2% assessed by FACS
analysis (not shown). CD3+ cells were directly used for
coculture experiments or activated with 10 ng/mL of phorbol
myristate acetate (PMA, Sigma) or with a mix of CD3
(1 𝜇g/mL, Miltenyi Biotec) and CD28 (2 𝜇g/mL, Miltenyi
Biotec) antibodies. Cocultures were established in direct
contact or by using transwells (1 𝜇m pore, Falcon, Becton
Dickinson) in 6- or 24-well plates (Corning Incorporated,
NY, USA). HLSCs and MSCs (1 × 105/wells) were seeded
into the lower compartment of the culture wells. Different
amounts of lymphocytes were loaded in the upper inserts
to obtain ratios of lymphocytes/HLSCs or MSCs of 1 : 1,
2 : 1, 5 : 1, and 10 : 1. In selected experiments, in noncontact
conditions, specific chemical antagonists of indoleamine
2,3-dioxygenase (IDO) and of prostaglandin E2 (PGE
2
)
such as 1-methyl-L-tryptophan (an inhibitor of IDO, Sigma,
0.5mM), indomethacin (Cox-1 and Cox-2 inhibitor, 10 𝜇M,
ICN Chemicals, Irvine, CA), and NS-398 (a specific Cox-
2 inhibitor, 1 𝜇M, Cayman Chemicals, Ann Arbor, MI)
were added to coculture (ratio lymphocytes/HLSCs 5 : 1).
All the experiments were conducted in duplicate. The T-
cell proliferation analysis was performed, after 3 days of
incubation, with the Muse Count & Viability Kit (Millipore,
Billerica, MA), following the manufacturer’s instruction,
and subsequently analysed by the Muse Cell Analyzer
(Merck Millipore, Massachusetts, USA). In particular, the
Muse Count & Viability Reagent contains fluorescent DNA-
binding dyes, which have differential permeability to viable
and nonviable cells, and provides absolute cell count and
viability data on cell suspensions. Both viable and nonviable
cells are differentially stained based on their permeability to
the DNA-binding dyes in the reagent. Data generated using
the Muse Cell Analyzer with the Muse software provide the
viable cell count (cells/mL); the total cell count (cells/mL);
and the percentage of viability of sample.
The amount of PGE
2
produced by HLSCs, in basal
condition and after cocultivation, was evaluated by ELISA
(R&D System, Minneapolis, MN).
2.4. NKPurification, Culture, andDegranulationAssay. Non-
activated NKs were obtained using the NK Cell Isolation Kit
(Miltenyi Biotec) that is an indirectmagnetic labelling system
for the isolation of untouched NKs from human PBMC. The
purity ofNKs after the isolationwas 95± 3%assessed by FACS
analysis (not shown). By this systemT-cells, B cells, stem cells,
dendritic cells, monocytes, granulocytes, and erythroid cells
were depleted using immunomagnetic beads.
After purification, NKs were maintained for 24 hours in
the presence of 15 ng/mL of interleukin- (IL-) 15 (Sigma).
After this incubation, NKs were cocultured in the presence
of or MSCs or HLSCs (ratio NK/MSC or HLSC 5 : 1) by
using direct coculture or in the transwell system. In selected
experiments, to test the functional role ofHLA-G, the specific
neutralizing antibody 87-G (10 𝜇g/mL, EXBIO) was added
in coculture experiments. After 4 days, NKs were harvested
and tested in the degranulation assay. The degranulation
assay is a highly sensitive method and its results are strictly
correlated with NK cytotoxicity [7]. The surface expression
of CD107a (Becton Dickinson) was analysed after 4 hours
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following activation of purifiedNKs with target cells (HLSCs,
MSCs, and K562, ATCC LGC Standards, Sesto San Giovanni,
Italy; original donor: female, 53 years old) at a 1 : 1 ratio in
the presence of a FITC labelled CD107a and of GolgiStop
(Becton Dickinson). The GolgiStop contains monensin that
prevents the acidification of endocytic vesicles avoiding the
degradation of reinternalized CD107a proteins from the sur-
face. Subsequently, NK cells were stained with APC labelled
anti-CD56 (Becton Dickinson) and analysed by FACS to
measure the percentage of CD107a positivity, as described
[7, 8]. In addition, the viability of HLSCs and MSCs was
tested using theMuseAnnexinV&DeadCell Kit (Millipore),
which permits enumeration of cells in various stage of
apoptosis (early and late). The viability of K562 cells was
evaluated by staining with propidium iodide (PI, 5𝜇g/mL,
Sigma). In this case, the K562 cells were labelled with green
fluorescent dye carboxyfluorescein diacetate succinimidyl
ester (CFSE, Molecular Probes, Invitrogen), to discriminate
K562 green cells from NKs cells by FACS analyses.
2.5. Human Monocyte Isolation and Differentiation in DCs.
Monocytes were isolated by plastic adherence. PBMCs were
plated at a concentration of 5 × 106 cell/mL in RPMI sup-
plemented with 10% FCS in 6-well flat-bottomed plates and
left to adhere in a 5% CO
2
incubator at 37∘C overnight.
Nonadherent cells were removed by 2 consecutive washes
with RPMI plus 10% FCS [9].
The next day, the DC differentiation medium, composed
by RPMI supplemented with 10% FCS, 20 ng/mL of IL-4
(Sigma), and 50 ng/mL of granulocyte-macrophage colony-
stimulating factor (GM-CSF, Sigma), was added. The purity
of the monocyte population was quantified through FACS
analyses, by positive staining for CD14 (87 ± 7%, not shown).
Monocytes were cocultured in the presence of 1 × 105 HLSCs
or MSCs seeded in transwells (1 𝜇m pore). After 2 days 1/3
of the medium was replaced and after 4 days 200 ng/mL of
lipopolysaccharide (LPS, Sigma) was added to the culture.
Complete differentiation was reached after 7 days. The same
experimental setting was repeated in the presence of NS-398
(1 𝜇M).The amount of PGE
2
produced after cocultivationwas
evaluated by ELISA.
TheDCdifferentiationwas assessed after 7 days of culture
using FITC, PE, and APC conjugated antibodies (all from
Becton Dickinson) for CD14, CD80, CD83, CD86, HLA-
DR, CD1a, CD40, CD54, 𝛼4 integrin, and 𝛼5 integrin. Data
were expressed as percentage of positive cells ± SD and as
geometric mean of fluorescence intensity ± SD.
Completely differentiated DCs in the presence or the
absence of HLSCs were treated with 50 𝜇g/mL of mitomycin
C (Sigma) in order to block their proliferation and cultured
in triplicate at a concentration of 2 × 104 in 96-well flat-
bottomed plate (Corning Incorporated) with 1 × 105 allo-
geneic CD3+ lymphocytes. As controls, CD3+ cells were
cultured alone or were treated with 10 ng/mL of PMA to
induce T-cell proliferation. Proliferation rates were analysed
after 2 days of coculture using 5-bromo-2󸀠-deoxyuridine
(BrdU) incorporation Kit (Roche, Basel, Switzerland). DNA
synthesis was detected as incorporation of BrdU into cellular
Table 1: List of primer sequences.
Gene name Sequence
COX-1 forward CTTGGGCCATGGGGTAGAC
COX-1 reverse TCTACCGAGGGCGGGTACA
COX-2 forward CTGGCAGGGTTGCTGGTG
COX-2 reverse CTTCAGCATAAAGCGTTTGCG
IDO forward GCCCTTCAAGTGTTTCACCAA
IDO reverse GCCTTTCCAGCCAGACAAATAT
Actin forward TGAAGATCAAGATCATTGCTCCTC
Actin reverse CACATCTGCTGGAAGGTGGAC
DNA. After 3 days of incubation, cells were then fixed with
0.5M ethanol/HCl and incubated with nuclease to digest the
DNA. BrdU incorporated into the DNA was detected using
an anti-BrdU peroxidase-conjugated mAb and visualized
with a soluble chromogenic substrate. Optical density was
measured with an ELISA reader at 405 nm.
2.6. RNA Extraction and Real Time Analysis. RNA was
extracted by Trizol (Life Technology, Carlsbad, CA) and
200 ng of total RNA was retrotranscribed using High Capac-
ity cDNA Reverse Transcription Kit (Applied Biosystems,
Foster City, CA). RT-PCR mix containing 1x SYBR GREEN
PCR Master Mix (Applied Biosystems), 100 nM of each
primer, listed in Table 1, and 5 ng of cDNA were assembled
using a 96-well StepOne Real Time System (Applied Biosys-
tems). Negative cDNA controls (no cDNA) were cycled in
parallel with each run.
Data are expressed as relative quantification using the
ΔΔCtmethod.Normalizationwasmade using actin as house-
keeping gene (Table 1).
2.7.Western Blot and Immunoprecipitation forHLA-G. HLSCs
were lysed for 15 minutes in a cold buffer containing 1%
Igepal, 5mM EDTA, 150mM NaCl, 50mM Tris-HCl (pH
8,0), 1mM phenylmethylsulfonyl fluoride (PMSF), and a
cocktail of protease and phosphatase inhibitors (all from
Sigma). Western blots were performed on 10% SDS-PAGE
(Bio-Rad, Hercules, CA). Nitrocellulose membranes (Bio-
Rad Laboratories) were probed with Abs specific for HLA-G
(1 : 200) and actin (1 : 300) (both from Santa Cruz Biotech-
nology) and with anti-mouse or anti-rabbit horseradish
peroxidase- (HRP-) conjugated secondary Abs (1 : 3000)
(Pierce, Waltham, MA) and developed using ECL plus detec-
tion reagents (GE Healthcare, Piscataway, NJ). Densitometry
analysis was performed using Quantity One image acquisi-
tion and analysis software (Bio-Rad Laboratories).
For immunoprecipitation analysis, the supernatants col-
lected from HLSCs were subjected to isopropanol precipita-
tion (1 : 4) overnight at−80∘C and then lysed with Ripa buffer.
Secondary antibodies were preincubated with protein A/G
plus agarose (Santa Cruz Biotechnology, Dallas, Texas, USA)
for 1 h at 4∘C to exclude nonspecific binding of proteins. The
tagged proteins were immunoprecipitated with appropriate
antibodies for 1 h at 4∘C and then with protein A/G plus
agarose overnight in a rotor at 4∘C. After centrifugation
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for 3 times in freshly prepared NP-40 buffer (50mM Tris-
HCl, 250mM NaCl, 2mM EDTA, 50mM NaF, and 0,1mM
Na
3
VO
4
), the pellets were used for SDS-PAGE (4%–20%
acrylamide gel, Bio-Rad).
2.8. Statistical Analyses. Statistical analysis was performed
with SPSS (IBM SPSS Statistics, version 20.0.0). Continuous
variables are presented as mean ± standard deviation or
as median (min-max), according to their distribution. The
difference between groups was analysed with Student’s 𝑡-
test (unpaired, 2-tailed), one-way ANOVA, or ANOVA with
Dunnet’s multiple comparison test and, when necessary, with
Bonferroni correction or with the nonparametric Wilcoxon
test. Significance level for all tests was set at 𝑝 < 0.05.
3. Results
3.1. HLSCs Suppress T-Cell Proliferation In Vitro. HLSCs are
similar to MSCs in that they constitutively express HLA class
I antigens but do not express HLA-DR and CD40, CD80, and
CD86 costimulatory molecules.
To determine the capacity of HLSCs to interfere with
T-lymphocyte proliferation, HLSCs were cocultured with
allogeneic CD3+ cells activated or not with PMA. No prolif-
eration was noted when purified T-lymphocytes were cocul-
tured in the presence of HLSCs or MSCs, at different ratios
(Supplementary Figure 1). Indeed, after 3 days of coculture,
HLSCs inhibited PMA-induced CD3+ cell proliferation in a
dose-dependent manner. In cell contact conditions, at a 5 : 1
lymphocyte : stem cell ratio, and in the presence of transwells,
the inhibitory effect of HLSCs was significantly greater than
that of MSCs (Figure 1(a) and Supplementary Figure 1).
Cell contact was not required for HLSC suppression of T-
cell proliferation, as HLSCs separated by a transwell were
almost as effective as those in direct contact with lymphocytes
(Figure 1(a) and Supplementary Figure 1). To confirm the
capacity of HLSCs to interfere with T-cell proliferation, we
also stimulated transwell cultures with anti-CD3 and CD28
antibodies and observed an inhibition of T-cell proliferation
in the presence of HLSCs at different cell ratios (Supplemen-
tary Figure 2).
The immunomodulatory effect of MSCs has been pre-
viously related to the production of two key soluble fac-
tors IDO and PGE
2
. To investigate the relevance of these
factors in HLSC suppression of T-cell proliferation, chem-
ical antagonists were added to lymphocyte-HLSC transwell
cocultures. The addition of 1-methyl-L-tryptophan (IDO-
inhibitor) or indomethacin (Cox-1 and Cox-2 inhibitor)
or NS-398 (Cox-2 inhibitor) significantly restored T-cell
proliferation (Figure 1(c)). In the absence of HLSCs, these
inhibitors did not interfere with T-lymphocyte proliferation
(not shown). These data indicated that cell contact was not
required and that Cox and IDO played a relevant role in
the HLSC-induced suppression of T-cell proliferation. We
therefore examined the mRNA levels of Cox-1 and Cox-2
and IDO in HLSCs and MSCs in basal condition and after
coculture, in the presence of transwells. HLSCs constitutively
expressed Cox-1 (Threshold cycle, Ct: 21 ± 1.2) and IDO (Ct:
31 ± 5.10). Moreover, Cox-1 expression is significantly more
expressed in HLSCs in comparison with MSCs (Figure 1(g)).
In both HLSCs and MSCs, the expression of Cox-2 and
IDO mRNAs significantly increased after coculture with
lymphocytes activated with PMA or with CD3 and CD28
antibodies (Figures 1(c)–1(f)). Nonactivated lymphocytes did
not induce upregulation of mRNA expression levels of Cox-
2 and IDO. We also tested if PMA might influence the
expression levels of Cox-2 and IDO in HLSCs and MSCs.
As shown in Figures 1(c)–1(f), PMA did not significantly
increase the expression levels of Cox-2 and IDO. Instead, the
conditioned medium (CM) derived from T-cells stimulated
with PMA induced a significant increase in both MSCs
and HLSCs. PGE
2
production also significantly increased
after culture with lymphocytes (Figure 1(h)). Stimulated T-
lymphocytes in the absence of HLSCs did not produce PGE
2
(Figure 1(h)).
3.2. HLSCs Do Not Stimulate NK Degranulation. In order
to compare the susceptibility of HLSCs to NK cell-mediated
lysis, a degranulation assay was performed based on the
detection of CD107a surface molecules on NK cell mem-
branes, after NK-HLSC coculture. Allogeneic NKs were
stimulated for 24 hours with IL-15 to increase their cyto-
toxic potential. Both HLSCs and MSCs were used as target
cells. Figure 2(a) shows that, after 4 hours of incubation,
degranulation of NKs in response to HLSCs was absent
(CD56+CD107+: 1 ± 0.5%). In contrast, MSCs induced NK
degranulation (CD56+CD107+: 9.3 ± 3.2%), as previously
described [8, 10, 11]. Moreover, the viability of HLSCs and
MSCs was evaluated after 4 hours of incubation with IL-15
activated NKs. In these conditions, the percentage of early
apoptotic HLSCs did not significantly increase, whereas the
percentage of early apoptotic MSCs significantly increased
(Figure 2(b)), confirming the data obtained by degranulation
assay. No significant difference was observed in the percent-
age of late apoptotic cells between HLSCs and MSCs.
3.3. HLSCs Impair NK Function on Target Cells. To study
whether HLSCs modulated NK activity, coculture exper-
iments were carried out in direct contact or by using
transwell inserts. Prestimulated NKs were cocultured with
HLSCs or MSCs and subsequently harvested to evaluate the
degranulation capacity against K562, a susceptible target cell
line. K562 cells induced degranulation of NKs prestimulated
with IL-15 (CD56+CD107+: 65 ± 8% (Figure 3(a))). Prein-
cubation of NKs with HLSCs, in contact condition or in
the presence of transwell, was able to significantly decrease
NK degranulation (CD56+CD107+: resp., 8.2 ± 1.5% and
2.5 ± 2%), in a manner comparable with the preincubation
with MSCs (CD56+CD107+: resp., 5.3 ± 2.2% and 7 ± 3%)
(Figure 3(b)). Moreover, after incubation with HLSCs, NKs
decreased their capacity to kill K562 cells (Figures 3(c) and
3(e)) and confirmed the data obtained by the degranulation
test. Also NKs incubated with MSCs decreased their capacity
to kill K562 cells (Figures 3(c) and 3(d)), but to a lesser extent
than HLSCs (Figure 3(e)).
We investigated whether the expression of HLA-G
molecule on HLSCs was involved in HLSC-induced inhi-
bition of NKs. Intracellular HLA-G was detected by flow
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Figure 1: HLSCs suppress T-lymphocyte proliferation through IDO and PGE
2
activity. (a) CD3+ lymphocytes were stimulated with PMA,
in the presence or the absence of MSCs or HLSCs at different ratio (lymphocytes: HLSCs/MSCs 1 : 1, 2 : 1, 5 : 1, and 10 : 1) in direct contact
or in the presence of transwells. The proliferation rate was evaluated after 3 days of coculture. Results are expressed as mean ± SD of 6
different experiments conducted in duplicate. 100% of proliferation corresponds to lymphocytes stimulated with PMA. Data were analysed
by nonparametric Wilcoxon test: ∗𝑝 < 0.05 lymphocytes stimulated with PMA cocultured in contact with HLSCs versus lymphocytes
stimulated with PMA cocultured in contact withMSCs; #𝑝 < 0.05 lymphocytes stimulated with PMA cocultured with HLSCs, in the presence
of transwells, versus lymphocytes stimulated with PMA cocultured with MSCs, in the presence of transwells. (b) IDO and PGE
2
are involved
in HLSC suppression of T-cell proliferation. CD3+ cells were stimulated with PMA in the presence of HLSCs (5 : 1 ratio) with or without
inhibitors of IDO (1-methyl-L-tryptophan) and Cox-1 and/or Cox-2 (indomethacin, NS-398) in the presence of transwells. The proliferation
rate was evaluated after 3 days. Results are expressed as mean ± SD of 6 different experiments in duplicate. 100% of proliferation corresponds
to lymphocytes stimulated with PMA. Data were analysed by ANOVA with Bonferroni correction: ∗𝑝 < 0.05 lymphocytes stimulated with
PMA cocultured with HLSCs and different inhibitors versus lymphocytes stimulated with PMA cocultured with HLSCs. (c) and (d) mRNA
expression levels of Cox-2 were evaluated inHLSCs (c) andMSCs (d) unstimulated, stimulatedwith PMA, after 3 days of coculture with CD3+
lymphocytes stimulated with PMA or with CD3/CD28 antibodies, stimulated with CM from T-cells stimulated with PMA, and cultured with
unstimulated lymphocytes. (e) and (f) mRNA expression levels of IDO were evaluated in HLSCs (e) and MSCs (f) unstimulated, stimulated
with PMA, after 3 days of coculture with CD3+ lymphocytes stimulated with PMA or with CD3/CD28 antibodies, stimulated with CM from
T-cells stimulated with PMA, and cultured with unstimulated lymphocytes. Cox-2 and IDO expression levels increased after coculture with
activated lymphocytes and after stimulation with CM. Data are expressed as relative quantification using ΔΔCt method. Normalization was
made using actin as housekeeping gene. Data were analysed by ANOVA with Bonferroni correction, ∗𝑝 < 0.05 gene expression of MSCs or
HLSCs after coculture with CD3+ cells stimulated with PMA or CD3/CD28 antibodies or after culture with CM versusMSCs or HLSCs alone.
(g) mRNA expression levels of COX-1 were evaluated in MSCs and HLSCs. Data are expressed as relative quantification using ΔΔCt method.
Normalization was made using actin as housekeeping gene. Data were analysed by Student’s 𝑡-test (unpaired, 2-tailed); ∗𝑝 < 0.05 COX-1
expression of HLSCs versus MSCs. (h) Cell supernatants from cocultures were harvested to detect PGE
2
production by ELISA. A significant
increased production of PGE
2
(𝑝 < 0.05) was observed after 3 days of coculture of CD3+ cells stimulated with PMA and cocultured with
HLSCs.
cytometry in HLSCs (69 ± 3.5%; Figure 4(a)) while only 10%
of cells were positive for membrane-bound HLA-G staining.
Western Blot analyses confirmed the presence of HLA-G
in HLSCs at different passages of culture (Figure 4(b)).
Soluble HLA-G was also present in HLSC supernatants
(Figure 4(c)). Experiments with blocking antibody against
HLA-G in transwells suggest that soluble HLA-G released
by HLSCs is involved in the inhibitory effect on NK activity
(Figure 4(d)).
3.4. HLSCs Suppress Monocyte-Derived DC Differentiation
and Maturation. Monocytes were cultured with GM-CSF
and IL-4 in the presence or the absence of HLSCs or
MSCs. After 4 days of culture, LPS was added to promote
the complete differentiation of DCs. After 7 days of differ-
entiation in these culture conditions, monocytes acquired
the characteristic shape and morphology of DCs and their
degrees of differentiation and maturation were assessed by
FACS analyses. In DCs that differentiated in the absence
of HLSCs and MSCs, the expression of CD14 (6 ± 4.8% of
positive cells) surface marker was almost abrogated; CD80,
CD86, and HLA-DR expression was high (72 ± 10%, 87 ±
8.6%, and 93 ± 6.9%, resp.) and the activation markers CD1a
and CD40 were increased (87 ± 6.4%, 23 ± 15.0%, resp.)
(Supplementary Figure 3 and Figure 5(a)). The presence of
HLSCs cultured in transwells interfered the differentiation
process of DCs, as shown by the persistence of CD14 (58
± 10.5%) expression on monocyte-derived cells (Supple-
mentary Figure 3 and Figure 5(a)) and inhibition of the
differentiation and maturation markers such as CD80 (38 ±
16.1%), CD86 (37 ± 20.3%), HLA-DR (51 ± 21.3%), CD1a (45
± 16.0%), and CD40 (2.8 ± 2.0%). Moreover, the expression
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Figure 2: HLSCs used as target for NKs do not elicit NK degranulation. (a) Representative (𝑛 = 5) cytofluorimetric analysis of CD107a
expression on NKs pretreated for 24 hours with IL-15 and incubated for 4 hours with MSCs or HLSCs, used as target cells in degranulation
assay. CD107a expression was used to quantify cytotoxic granule exocytosis. After 4 hours of cocultivation with MSCs, a small percentage
of NKs (about 8%) start to express CD107a; instead the NKs incubated with HLSCs did not degranulate and so did not express CD107a. (b)
Early and late apoptosis of HLSCs and MSCs were evaluated after 4-hour incubation with NKs. Data are expressed as mean ± SD of percent
variation of apoptotic cells. Results were obtained from 3 independent experiments performed in duplicate. Data were analysed by Student’s
𝑡-test (unpaired, 2-tailed); ∗𝑝 < 0.05MSC cocultured with NKs versus control MSCs.
of 𝛼4 integrin and 𝛼5 integrin adhesion molecules and CD54
decreased in the presence of HLSCs (Supplementary Figure
3 and Figure 5(a)). The mean fluorescence intensity (GEO
mean) was also analysed for several surface markers. The
intensity for CD80, CD86 and HLA-DR, CD54, and 𝛼5
integrin was significantly lower in DCs cultured with HLSCs
comparedwithDCs differentiated in the absence of stem cells
(Figure 5(b)). The effect of HLSCs on DC differentiation was
comparable to that previously described for MSCs (Figures
5(a) and 5(b)) [12, 13]. Notably, the presence of HLSCs did
not affect DCs viability (not shown) as already demonstrated
for MSCs [12].
DCs promote antigen-specific T-cell activation. DCs
stimulated with LPS were able to induce CD3+ lymphocyte
proliferation. When DCs predifferentiated in the presence
of HLSCs were used, a significant reduction of T-cell pro-
liferation was observed (Figure 5(c)). These results confirm
functional impairment of DC differentiation in the presence
of HLSCs.
The action of MSCs on DC differentiation has been
ascribed to the production of many soluble factors, of which
the most important seems to be PGE
2
[14]. The presence of
PGE
2
was quantified by ELISA assay in supernatant of DCs
differentiated in the presence or the absence of HLSCs (3 and
7 day of culture) and in HLSC supernatant (Figure 6(a)). As
shown in Figure 6(a), HLSCs produced PGE
2
constitutively;
moreover, the amount of this mediator was significantly
increased in coculture with DCs. DCs cultured alone did
not produce PGE
2
(Figure 6(a)). mRNA levels of Cox-1 and
Cox-2 were evaluated in HLSCs and DCs when cocultured.
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Figure 3: Continued.
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Figure 3: HLSCs inhibit NK activity. NKs, prestimulated for 24 hours with IL-15, were cocultured at the ratio of 5 : 1 with MSCs or HLSCs in
direct contact or in transwells for 4 days. Subsequently, the NKs were challenged with a NK-susceptible target cell line (K562 cell line) and
their degranulation was evaluated. (a) Representative (𝑛 = 3) cytofluorimetric analysis of CD107a expression onNKs (NKCTRL) and onNKs
after 4 hours of incubation with K562 cells (NK CTRL+K562). CD107a was detectable on NKmembrane after incubation with K562 cells. (b)
Representative (𝑛 = 5) cytofluorimetric analysis of CD107a expression on NKs in the presence of K562 and after 4 days of incubation with
MSCs or HLSCs. NKs cocultured with MSCs and HLSCs reduced their capacity to degranulate in the presence of specific target cells. (c)–(e)
The death of K562 cells labelled with CFSE, which were evaluated by PI staining, after incubation for 4 hours with NKs stimulated with IL-15
(c) and cocultured, in the presence of transwells, for 4 days with MSCs (d) or with HLSCs (e).
mRNA levels of Cox-1 and Cox-2 were significantly higher in
HLSCs comparedwithDCs, suggesting that PGE
2
wasmainly
secreted by HLSCs (Figure 6(b)).
In addition, to test the biological role of PGE
2
, NS-398
was added to DC culture in the presence of HLSCs. PGE
2
inhibition significantly reverted the negative effect of HLSCs
on DC differentiation (Figure 6(c)). Taken together, these
data suggest that PGE
2
plays a central role in the inhibition
of DC function.
4. Discussion
HLSCs are a population of liver stem-like cells easily obtain-
able from human adult liver [1–3]. They have a great prolif-
eration potential and remain stable for over thirtieth culture
passages, without acquiring chromosomal aberrations. Good
manufacturing practice protocols to obtain and expand
HLSCs have been established in our laboratory. Moreover,
HLSCs have been approved by Italian Regulatory Agency for
a phase I study, fulfilling all the release criteria for cellular
therapies.
A critical issue in cell therapy is rejection, resulting from
the immune-incompatibility between donor and recipient. In
this paper, we show that HLSCs have immunomodulatory
properties that may obviate the major obstacle for the
application of these cells in cell therapy.
HLSCs did not expressHLAclass II and the costimulatory
molecules CD40, CD80, and CD86. In addition, HLSCs
inhibit (i) proliferation ofmitogen-stimulatedT-lymphocytes
in a dose-dependent manner, (ii) degranulation capacity of
NKs against a susceptible target cancer cell line, and (iii) DC
differentiation and maturation.
The inhibitory effect of HLSCs on T-lymphocyte pro-
liferation was dose-dependent (ratio lymphocytes to stem
cells: 1 : 1, 2 : 1, 5 : 1, and 10 : 1) and was greater than that of
MSCs. HLSC-dependent inhibition of T-cell proliferation
was observed with a ratio up to 10 : 1. Furthermore, cell
contact was not required for this effect, as HLSCs separated
by a transwell were almost as effective as those in direct
contact with lymphocytes. The mechanisms responsible for
the suppression of T-lymphocyte proliferation also have
been evaluated. HLSCs constitutively expressed Cox-1 and
IDO; their mRNA levels increased after coculture with T-
lymphocytes. Moreover, the addition of chemical antagonists
of these enzymes significantly restored T-cell proliferation,
indicating that Cox and IDO activities are involved in
the antiproliferative effect of HLSCs. These observations
are similar to that reported for MSCs [7, 15, 16]. It has
been shown that PGE
2
synthesis inhibition mitigated MSC-
mediated suppression of T-lymphocytes [16, 17] and that IDO
activity was involved in MSC-induced inhibition of T-cell
proliferation [15].
Furthermore, it was found that HLSCs did not elicit a
significant NK response. In contrast, MSCs were sensitive
to NK as they induced high NK degranulation [8, 10, 11].
Therefore, HLSCs seem to be more protected than MSCs
from allogeneic NK lysis. MSCs from other sources such
as adipose tissue and embryonic stem cells have been also
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Figure 4: HLA-G expression mediates the HLSC activity on NKs. (a) Representative (𝑛 = 4) cytofluorimetric analysis of HLA-G expression
onHLSCmembrane and after intracytoplasmic staining, using the specificMEMG/9 antibody (native form for humanHLA-G1). (b)Western
Blot analyses confirmed the presence of HLA-G in HLSCs at different passages of culture (p4, p6, and p8). (c) Soluble HLA-G is present in
HLSC supernatants, as indicated byWestern Blot after immune-precipitation with specific antibody. HLA-G protein expression was detected
through mAb 4H84, resulting in specific band corresponding to the expected molecular weight of 39 kDa. (d) Representative (𝑛 = 4)
cytofluorimetric analysis of CD107a expression on NKs in degranulation assay, after 4 days of incubation with HLSCs in the presence or
the absence of specific blocking antibody against HLA-G (87-G). HLSCs, via the secretion of HLA-G reduced NK degranulation, as a specific
neutralizing anti-HLA-G antibody restored degranulation activity to levels similar to those following incubation of NKs with K562 cells alone
(CD56+CD107+: 87 ± 5% inNKCTRL, 5.5 ± 4% inNKs cocultured withHLSCs, and 90 ± 5.3% inNKs cocultured withHLSCs in the presence
of blocking antibody).
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Figure 5: HLSCs suppress monocyte-derived DC differentiation and DC ability to stimulate T-cell proliferation. (a) Mean percentages ±
SD of the expression of CD14, CD83, CD40, CD80, CD86, HLA-DR, CD1a, CD54, and 𝛼4 and 𝛼5 integrin of DCs differentiated in the
presence of HLSCs or MSCs or in the absence of stem cells (CTRL) evaluated by cytofluorimetric analyses. Results were obtained from 8
independent experiments. ANOVA with Dunnet’s multicomparison test was performed: ∗𝑝 < 0.05 stem cells versus CTRL; ∗∗𝑝 < 0.001
stem cells versus CTRL. (b) Mean fluorescence intensity expressed as GEO mean ± SD of CD40, CD1a, CD80, 𝛼5 integrin, CD86, HLA-DR,
and CD54 of DCs differentiated in the presence of HLSCs or MSCs or in the absence of stem cells (CTRL). Results were obtained from 8
independent experiments. ANOVAwith Dunnet’s multicomparison test was performed: ∗𝑝 < 0.05 stem cells versus CTRL; ∗∗𝑝 < 0.001 stem
cells versus CTRL. (c) DCs differentiated in the presence of HLSCs or in the absence were plated at cell concentration of 2 × 104 with 1 ×
105 T CD3+ lymphocytes. Forty-eight hours later, T-cell proliferation was assessed. Data are expressed as mean ± SD of percent variation of
T-cell proliferation in the presence or the absence of DCs differentiated in the presence of HLSCs with respect to T-cell proliferation in the
presence of DCs alone (established as 100%). Results were obtained from 5 independent experiments. Data were analysed by Student’s 𝑡-test
(unpaired, 2-tailed); ∗𝑝 < 0.05 DC (HLSC)+T versus DC+T.
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Figure 6: PGE
2
mediates the HLSC activity on monocyte-derived DCs. (a) Cell supernatants were harvested to detect PGE
2
production
by ELISA after 3 and 7 days of coculture of DCs in the presence or the absence of HLSCs. ANOVA with Dunnet’s multicomparison test
was performed: ∗∗𝑝 < 0.001 DC+HLSC versus HLSC. (b) mRNA expression levels of Cox-1 and Cox-2 were evaluated in HLSCs and in
DCs cocultured for 7 days. Cox-1 and Cox-2 expression levels were higher in HLSCs compared with DCs. Data are expressed as relative
quantification (RQ)usingΔΔCtmethod.Normalizationwasmade using actin as housekeeping gene.ANOVAwithDunnet’smulticomparison
test was performed: ∗∗𝑝 < 0.001HLSC versus DC. (c) Mean of percentages ± SD of CD14, CD80, CD86, CD1a, CD54, and 𝛼4 and 𝛼5 integrin
of positive DCs differentiated in the presence (HLSC) or in the absence (CTRL) of HLSCs or stimulated with NS-398. Results were obtained
from 4 independent experiments. ANOVA with Dunnet’s multicomparison test was performed: ∗𝑝 < 0.05 HLSC versus HLSC+NS-398;
∗∗
𝑝 < 0.001HLSC versus HLSC+NS-398.
shown to be more resistant to NK lyses than bone marrow
MSCs [8, 18, 19]. This may represent an advantage for their
application in cellular therapies.
Another important aspect to be considered, related to
NK/HLSC interaction, was whether the NKs cocultured with
HLSCs modify their functionality over other susceptible
target cells. The degranulation capacity of NKs on K562
cancer cell line was reduced after coculture with HLSCs
also in the absence of contact. Similar inhibition of NK
degranulation on target cells was observed for MSCs [11].
Previous studies demonstrated that the secretion of soluble
HLA-G plays an important role in the biological effect of
MSCs [20, 21]. HLA-G is a nonclassical HLA class I molecule
with low polymorphism and a restricted tissue distribution
(e.g., trophoblasts). HLA-G is known to confer to the fetus
protection against the maternal immune system [22]. The
addition of the specific blocking antibody against HLA-G
to the NK/HLSC coculture prevented the inhibitory effect
of HLSCs on NK degranulation. This observation, together
with the presence of soluble HLA-G in HLSC supernatant,
suggests a possible role of this molecule in NK modulation.
The effect of HLSCs on DC differentiation was also
comparable to that previously described for MSCs [11–13,
23]. In the presence of HLSCs, the differentiation of CD14+
monocytes into DCs was impaired. In the appropriate culture
condition and in the presence of HLSCs, monocytes retained
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the expression of CD14 and did not upregulate specific
dendritic markers of maturation and activation.The addition
of a specific PGE
2
inhibitor reverted this effect suggesting that
PGE
2
secreted by HLSCs plays a central role in the inhibitory
effect of HLSCs on DC differentiation. In addition, HLSCs
also efficiently suppressed the ability of DCs to stimulate T-
cell-activation and proliferation.
The immunomodulatory effect of HLSCs in physiological
conditions is hard to demonstrate in vivo as this population
has been described only in humans. In addition, the ratio of
HLSCs/lymphocytes used in vitro possible does not represent
ratio present in the human liver. However, if used therapeu-
tically, the amount of HLSCs administered may account for
an in vivo immunomodulatory effect as shown for MSCs
which in patients with graft versus host disease are repeatedly
injected at doses in the range of 1–1.5 × 106 cells/Kg [24, 25].
5. Conclusions
The results of the present study indicate that HLSCs display
optimal characteristics for cell therapy in an allogeneic
setting. In fact, they modulate different aspects of the
immune response including immunogenicity and T and NK
responses. These results may be relevant for cell transplanta-
tion since these cells received the Orphan Drug designation
from the European Medical Agency for ornithine transcar-
bamylase deficiency (EU/3/11/904), carbamoyl-phosphatase
synthase deficiency (EU/3/12/971), and acute liver failure
(EU/3/12/983).
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